Allogeneic T cells are engineered ex vivo with a lentiviral vector to express an EBV-specific, HLA-A*02:01/11:01/24:02–restricted T-cell receptor. Upon recognition of EBV-derived peptides presented on MHC class I of infected host cells, the introduced TCR triggers T-cell activation and cytotoxic effector functions (perforin/granzyme, Fas–FasL) and cytokine release, leading to targeted elimination of EBV-infected cells and reduction of EBV-driven inflammation (e.g., in EBV-HLH or persistent EBV infection).